Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor‐tyrosine kinase inhibitor in lung cancer
Hiroshi Mizuuchi(Kindai University), Tetsuya Mitsudomi(Kindai University)
Cited by 31
Related Papers
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro
|Journal of Thoracic Oncology|2019|174
The insulin‐like growth factor 1 receptor causes acquired resistance to erlotinib in lung cancer cells with the wild‐type epidermal growth factor receptor
|International Journal of Cancer|2014|53
Collateral Chemoresistance to Anti-Microtubule Agents in a Lung Cancer Cell Line with Acquired Resistance to Erlotinib
|PLoS ONE|2015|17
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression
|PLoS ONE|2016|17
Secondary Mutations of the EGFR Gene That Confer Resistance to Mobocertinib in EGFR Exon 20 Insertion
|Journal of Thoracic Oncology|2023|16